Immunocore Tebentafusp Shows Survival Benefit In Untreated Eye Cancer Patients

Immunocore Holdings Plc IMCR announced that data from a Phase 3 randomized trial comparing tebentafusp (IMCgp100) with investigator's choice in first-line metastatic uveal melanoma (mUM) had been published in The New England Journal of Medicine.
The paper concluded that tebentafusp is the first systemic treatment to show a survival benefit in mUM (eye cancer) and should become a new treatment option.
Results demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS).
The OS Hazard Ratio (HR) in the intent-to-treat population favored tebentafusp, HR=0.51 over investigator's choice (82% pembrolizumab; 12% ipilimumab; 6% dacarbazine).
Treatment-related adverse events were manageable and consistent with the proposed mechanism.
Tebentafusp has been granted Breakthrough Therapy Designation, Fast Track designation, and orphan drug designation by the FDA and Promising Innovative Medicine designation in the U.K. for the same indication.
Price Action: IMCR stock closed at $35.97 on Wednesday.